Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Preclinical Results on MYCO-006 Series

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD. The company has announced promising pharmacokinetics and pharmacodynamics (“PKPD”) results from the MYCO-006 family in mouse models. According to the update, the mice model data indicates considerably shorter half-life and accelerated onset while retaining generation-1 MDMA features. The objective of this effort has been to develop medications that mirror the qualities and effects of Gen-1 MDMA with a shorter duration. Mydecine believes that these enhanced features will significantly improve their usability in existing medical and clinical settings, removing the need for a specialized “psychedelic clinic” where clinicians can use the MYCO-006 drugs to improve the efficacy of therapy sessions while eliminating the need for further post-session monitoring of the patent. “Mydecine is happy to have met our development target of developing shorter acting MDMA-like compounds and looks forward to delivering these medications in human trials in the near future,” said Robert Roscow, CSO of Mydecine. “This medication family has tremendous potential to aid people in need.”

To view the full press release, visit https://ibn.fm/yvxyZ

About Mydecine Innovations Group Inc.

Mydecine is a publicly traded pre-revenue biopharmaceutical R&D firm founded in early 2020 with partners and staff throughout North America and Europe. Mydecine is a company founded on the idea of expanding physicians’ access to serotonin-modulating drugs. Recent studies have shown the promise of such psychedelic compounds as psilocybin and MDMA for treating intractable conditions, including pain, anxiety, addiction, and PTSD. Mydecine believes that these compounds can be improved through modern drug chemistry to be both safer for patients and more usable for physicians. Mydecine is developing novel drugs for target indications with high mortality rates that lack innovation and are controlled by major corporations. The Company has developed several prodrug families, starting with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial through John Hopkins University. Mydecine is also developing MYCO-006—MDMA-derived short-acting drug analogs designed for treating various conditions, including anxiety and pain. Mydecine is utilizing cutting-edge AI and pharma research infrastructure within the University of Alberta to develop and manufacture new medications and plans to make them affordable and accessible to the general population when FDA approval is granted. The team is passionate about its mission and committed to making a healthy difference in people’s lives. For more information about the company, visit www.Mydecine.com.

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.